ArticleRheumatology (Oxford, England)2026
Canakinumab dosing intervals in pediatric colchicine-resistant FMF: outcomes and predictors of successful extension in a real-world cohort.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCanakinumab is widely used in colchicine-resistant familial Mediterranean fever (FMF), yet data on interval adjustment strategies and predictors of successful extension remain limited. This study evaluated clinical and inflammatory outcomes across dosing interval groups and identified factors associated with successful interval extension.
methodsThis retrospective single-centre study included 60 pediatric patients with colchicine-resistant FMF treated with canakinumab. Patients were stratified into stable interval (group 1, n = 14), successful interval extension (group 2, n = 24) and unsuccessful interval extension (group 3, n = 22). Longitudinal C-reactive protein (CRP) trajectories were analysed using linear mixed-effects models. Clinical outcomes were compared across groups, and predictors of successful interval extension were assessed using multivariable logistic regression with Firth's penalized method as a sensitivity analysis.
resultsFollowing canakinumab initiation, CRP levels declined rapidly and stabilized after month 3, while the median annual attack rate decreased from 7 (4-12) to 1.1 (0.5-2.1) attacks per patient-year. Inflammatory trajectories did not differ across groups. Despite similar CRP dynamics, complete remission rates differed significantly (57.1%, 45.8% and 27.3% in Groups 1-3, respectively; P = 0.005), and all patients in group 3 experienced attacks. Arthritis at disease onset was independently associated with successful interval extension (OR = 7.14, 95% CI 1.26-40.41, P = 0.026), with consistent direction in Firth analysis (OR = 5.51, 95% CI 1.08-28.23, P = 0.081).
conclusionAlthough canakinumab achieves sustained inflammatory suppression, biochemical improvement does not ensure comparable clinical control. Clinical phenotype, particularly arthritis at onset, may guide individualized interval adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.